Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Moraxellaceae Infections D045828 3 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Communicable Diseases, Emerging D021821 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Multiple Sclerosis, Relapsing-Remitting D020529 7 associated lipids
Focal Nodular Hyperplasia D020518 1 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acquired Hyperostosis Syndrome D020083 1 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Fang X et al. [Inhibitory activity of azithromycin on biofilm synthesis and synergism between azithromycin and fleroxacin on Pseudomonas aeruginosa in biofilms]. 1998 Zhonghua Jie He He Hu Xi Za Zhi pmid:11360505
Palomar R et al. Effectiveness and safety of azithromycin on the treatment of cyclosporine-induced gingival overgrowth. 1998 Nephron pmid:9609470
Matlow A et al. Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents. 1998 Antimicrob. Agents Chemother. pmid:9593171
Kozyrskyj AL et al. Treatment of acute otitis media with a shortened course of antibiotics: a meta-analysis. 1998 JAMA pmid:9624028
Nowicki M et al. Partial regression of advanced cyclosporin-induced gingival hyperplasia after treatment with azithromycin. A case report. 1998 Ann. Transplant. pmid:10234432
Karcioglu ZA et al. Pharmacokinetics of azithromycin in trachoma patients: serum and tear levels. 1998 Ophthalmology pmid:9544640
Edelstein PH Legionnaires' disease. 1998 N. Engl. J. Med. pmid:9441231
Hillis SD et al. Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use-effectiveness study in public health settings. 1998 Sex Transm Dis pmid:9437777
Andersen SL et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. 1998 Clin. Infect. Dis. pmid:9455524
Chia JK et al. Azithromycin for the treatment of cat-scratch disease. 1998 Clin. Infect. Dis. pmid:9455538
Peterson J and Treadway G Impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. 1998 Clin. Infect. Dis. pmid:9455579
Holmberg SD et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. 1998 JAMA pmid:9459473
Rajyaguru JM and Muszynski MJ Sensitization of Burkholderia cepacia to antibiotics by cationic drugs. 1998 J. Antimicrob. Chemother. pmid:9533472
Varvara G and D'Arcangelo C [The evaluation of the clinical efficacy and tolerance of azithromycin in odontostomatological infections]. 1998 Jan-Feb Minerva Stomatol pmid:9578649
Kalenić S et al. Helicobacter pylori: in vitro induction of resistance to azithromycin. 1998 Jan-Feb Chemotherapy pmid:9444404
Russell TS et al. Eradication of Cryptosporidium in a child undergoing maintenance chemotherapy for leukemia using high dose azithromycin therapy. 1998 Jan-Feb J. Pediatr. Hematol. Oncol. pmid:9482419
Rapp RP Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions. 1998 Jul-Aug Ann Pharmacother pmid:9681095
Zaremba CD Comment: could acetaminophen have played a role in a possible azithromycin-warfarin interaction? 1998 Jul-Aug Ann Pharmacother pmid:9681108
Dohmen W and Seelis RE The role of azithromycin in the treatment of Helicobacter pylori infection - a retrospective report. 1998 Jul-Aug Infection pmid:9867486
Diculencu D et al. [The postantibiotic effect of azithromycin on respiratory pathogens]. 1998 Jul-Dec Rev Med Chir Soc Med Nat Iasi pmid:10756861
Shafran SD Prevention and treatment of disseminated Mycobacterium avium complex infection in human immunodeficiency virus-infected individuals. 1998 Jul-Sep Int. J. Infect. Dis. pmid:9831675
Venuta A et al. Azithromycin compared with clarithromycin for the treatment of streptococcal pharyngitis in children. 1998 Jun-Jul J. Int. Med. Res. pmid:9718470
LaCARP opens clinical trials to patients of all primary care providers. 1998 Mar-Apr Fac Notes (New Orleans La) pmid:11365129
Chakrabarti MK et al. Evaluation of different antibiotics in inhibiting colonization of Vibrio cholerae O1 and O139 in the rabbit intestine. 1998 Mar-Apr Chemotherapy pmid:9551241
Clement PA and de Gandt JB A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of sinusitis in adults. 1998 Mar-Apr J. Int. Med. Res. pmid:9602984
Schuster FL and Visvesvara GS Efficacy of novel antimicrobials against clinical isolates of opportunistic amebas. 1998 Nov-Dec J. Eukaryot. Microbiol. pmid:9864851
Bonoan JT et al. Life-threatening babesiosis in an asplenic patient treated with exchange transfusion, azithromycin, and atovaquone. 1998 Nov-Dec Heart Lung pmid:9835673
Adriaenssen CF Comparison of the efficacy, safety and tolerability of azithromycin and co-amoxiclav in the treatment of acute periapical abscesses. 1998 Oct-Nov J. Int. Med. Res. pmid:9924711
Montenez JP et al. Interactions of macrolide antibiotics (Erythromycin A, roxithromycin, erythromycylamine [Dirithromycin], and azithromycin) with phospholipids: computer-aided conformational analysis and studies on acellular and cell culture models. 1999 Toxicol. Appl. Pharmacol. pmid:10198278
Amsden GW Pharmacological considerations in the emergence of resistance. 1999 Int. J. Antimicrob. Agents pmid:10204634
Retsema JA Susceptibility and resistance emergence studies with macrolides. 1999 Int. J. Antimicrob. Agents pmid:10204635
Wubbel L et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. 1999 Pediatr. Infect. Dis. J. pmid:10048679
Eagan L Data on HIV infection in women expands. 1999 Posit Living pmid:11367336
Wyrick PB et al. Persistent chlamydial envelope antigens in antibiotic-exposed infected cells trigger neutrophil chemotaxis. 1999 J. Infect. Dis. pmid:10068592
Shirtliff ME et al. Oral rifampin plus azithromycin or clarithromycin to treat osteomyelitis in rabbits. 1999 Clin. Orthop. Relat. Res. pmid:10078148
Ong EL Prophylaxis against disseminated Mycobacterium avium complex in AIDS. 1999 J. Infect. pmid:10090497
Anderson JL et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. 1999 Circulation pmid:10096928
Howard KB et al. Azithromycin versus erythromycin for community-acquired pneumonia: a cost-minimization analysis. 1999 Am J Health Syst Pharm pmid:10478989
Taylor WR et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. 1999 Clin. Infect. Dis. pmid:10028075
Shanks GD Possible options for malaria chemoprophylaxis on the horizon. 1999 J Travel Med pmid:23573551
Mabey D and Bailey R Eradication of trachoma worldwide. 1999 Br J Ophthalmol pmid:10535853
Muhlestein JB Animal models of chlamydia and atherosclerosis. 1999 Am. Heart J. pmid:10539862
Gupta S Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease. 1999 Am. Heart J. pmid:10539869
Dunne M WIZARD and the design of trials for secondary prevention of atherosclerosis with antibiotics. 1999 Am. Heart J. pmid:10539870
Grayston JT Design of future intervention studies for Chlamydia pneumoniae in atherosclerosis. 1999 Am. Heart J. pmid:10539875
Goldstein EJ et al. Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. 1999 Antimicrob. Agents Chemother. pmid:10543769
Watt G et al. Azithromycin activities against Orientia tsutsugamushi strains isolated in cases of scrub typhus in Northern Thailand. 1999 Antimicrob. Agents Chemother. pmid:10543774
Schachter J et al. Azithromycin in control of trachoma. 1999 Lancet pmid:10466664
Chern KC et al. Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. 1999 Br J Ophthalmol pmid:10574809
Kutlin A et al. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. 1999 Antimicrob. Agents Chemother. pmid:10471577
Bui KQ et al. Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis. 1999 Antimicrob. Agents Chemother. pmid:10471584
Koletar SL et al. Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. 1999 Antimicrob. Agents Chemother. pmid:10582873
Dunne MW et al. Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. 1999 Lancet pmid:10489947
Nicolau DP et al. Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model. 1999 Antimicrob. Agents Chemother. pmid:10582906
Blandizzi C et al. Periodontal tissue disposition of azithromycin in patients affected by chronic inflammatory periodontal diseases. 1999 J. Periodontol. pmid:10505797
Zarantonelli L et al. Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. 1999 Antimicrob. Agents Chemother. pmid:10508026
Jackson LA et al. Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease. 1999 J. Antimicrob. Chemother. pmid:10511413
Ghaffar F et al. Increased carriage of resistant non-pneumococcal alpha-hemolytic streptococci after antibiotic therapy. 1999 J. Pediatr. pmid:10547251
Fong IW et al. Can an antibiotic (macrolide) prevent Chlamydia pneumoniae-induced atherosclerosis in a rabbit model? 1999 Clin. Diagn. Lab. Immunol. pmid:10548582
[Short-term therapy with Azithromycin. Pneumonia-pathogens, most commonly encountered in practice, easily targeted]. 1999 Internist (Berl) pmid:10549000
Foulds G et al. The effect of azithromycin on the pharmacokinetics of indinavir. 1999 J Clin Pharmacol pmid:10434237
Umut S et al. Determination of the etiological organism during acute exacerbations of COPD and efficacy of azithromycin, ampicillin-sulbactam, ciprofloxacin and cefaclor. Turkish Thoracic Society COPD Working Group. 1999 J Chemother pmid:10435684
Krichhoff RM et al. Determination of azithromycin in gastric biopsy samples. 1999 Int J Clin Pharmacol Ther pmid:10442511
Kamath R Antibiotic therapy for Salmonella enteritis. 1999 J Paediatr Child Health pmid:10457286
Chiu CH et al. A clinical trial comparing oral azithromycin, cefixime and no antibiotics in the treatment of acute uncomplicated Salmonella enteritis in children. 1999 J Paediatr Child Health pmid:10457295
Grimes DA and Schulz KF Prophylactic antibiotics for intrauterine device insertion: a metaanalysis of the randomized controlled trials. 1999 Contraception pmid:10592851
Ouchi K Chlamydia pneumoniae and atherosclerosis. 1999 Jpn. J. Infect. Dis. pmid:10738358
Oliva S et al. Successful treatment of widely disseminated acanthamoebiasis. 1999 South. Med. J. pmid:9932828
Ghirga G et al. Inefficacy of a 3-day course of azithromycin in preventing acute rheumatic fever after group A streptococcal infection (scarlet fever) in an 8-year-old child. 1999 J. Pediatr. pmid:9880464
Karcioglu ZA et al. Pharmacokinetics of azithromycinin rabbit lacrimal glands and conjunctiv a. 1999 Ophthalmic Res. pmid:9831822
Johnson MM et al. Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. 1999 Antimicrob. Agents Chemother. pmid:10428903
Credito KL et al. Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. 1999 Antimicrob. Agents Chemother. pmid:10428930
Wirnsberger GH et al. Chronic bacterial inflammation of the gum: the main risk factor for posttransplant gingival hyperplasia? 1999 Clin. Nephrol. pmid:9988152
Cazzola M et al. Comparative study of dirithromycin and azithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis. 1999 J Chemother pmid:10326742
Preheim LC et al. Ethanol feeding does not affect the efficacy or pharmacokinetics of azithromycin, trovafloxacin, or ceftriaxone in a rat model of pneumococcal pneumonia. 1999 Alcohol. Clin. Exp. Res. pmid:10371404
Drugs for sexually transmitted infections. 1999 Med Lett Drugs Ther pmid:10906932
Alvarez-Elcoro S and Enzler MJ The macrolides: erythromycin, clarithromycin, and azithromycin. 1999 Mayo Clin. Proc. pmid:10377939
Scharfstein JA et al. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS. 1999 Int J Technol Assess Health Care pmid:10874380
Principi N and Esposito S Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. 1999 Drug Saf pmid:9935275
Alvarez Gutiérrez FJ et al. [A randomized comparative study of 3 days of azithromycin treatment and 10 days of cefuroxime treatment in exacerbations in patients with chronic obstructive pulmonary disease]. 1999 Med Clin (Barc) pmid:10472596
Amsden GW et al. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. 1999 Antimicrob. Agents Chemother. pmid:9869584
Breitschwerdt EB et al. Efficacy of doxycycline, azithromycin, or trovafloxacin for treatment of experimental Rocky Mountain spotted fever in dogs. 1999 Antimicrob. Agents Chemother. pmid:10103185
Laine L et al. Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. 1999 Am. J. Gastroenterol. pmid:10201465
Taylor KI and Taylor HR Distribution of azithromycin for the treatment of trachoma. 1999 Br J Ophthalmol pmid:10396186
Vcev A et al. High dose omeprazole plus amoxicillin and azithromycin in eradication of Helicobacter pylori in duodenal ulcers. 1999 Helicobacter pmid:10352088
Cinti S et al. Killing of Mycobacterium avium by neutrophils and monocytes from AIDS patients treated with recombinant granulocyte-macrophage colony-stimulating factor. 1999 J. Infect. Dis. pmid:10353887
Lombardo L et al. Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and azithromycin: failure of a "promising" association. 1999 Ital J Gastroenterol Hepatol pmid:10379493
Moore PA Dental therapeutic indications for the newer long-acting macrolide antibiotics. 1999 J Am Dent Assoc pmid:10492541
Trautmann M et al. Combined activity of azithromycin and lansoprazole against Helicobacter pylori. 1999 Helicobacter pmid:10382125
de Vries PI et al. Short course of azithromycin/artesunate against falciparum malaria: no full protection against recrudescence. 1999 Trop. Med. Int. Health pmid:10402979
Horgan SE et al. Use of a low nutrient culture medium for the identification of bacteria causing severe ocular infection. 1999 J. Med. Microbiol. pmid:10403423
Donati M et al. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. 1999 J. Antimicrob. Chemother. pmid:10404322
Neiger R et al. Use of a urea breath test to evaluate short-term treatments for cats naturally infected with Helicobacter heilmannii. 1999 Am. J. Vet. Res. pmid:10407483
Garey KW et al. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. 1999 Antimicrob. Agents Chemother. pmid:10223928
Ouadrhiri Y et al. Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon. 1999 Antimicrob. Agents Chemother. pmid:10223943
Könönen E et al. beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children. 1999 Antimicrob. Agents Chemother. pmid:10223950
Bergman KL et al. Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. 1999 Antimicrob. Agents Chemother. pmid:10223956
Akova M et al. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. 1999 Antimicrob. Agents Chemother. pmid:10223958
Taylor H Towards the global elimination of trachoma. 1999 Nat. Med. pmid:10229224
Lietman T et al. Global elimination of trachoma: how frequently should we administer mass chemotherapy? 1999 Nat. Med. pmid:10229236